Navigation Links
Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Date:5/29/2009

KRX-0401 Demonstrates Impressive Single Agent Efficacy in Patients who Progressed after Failing Treatment Either with a VEGF Receptor Inhibitor or after Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor

NEW YORK, May 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced data on the clinical activity of KRX-0401 (perifosine), the Company's Akt-inhibitor for cancer, as a treatment for advanced renal cell carcinoma. Abstract #5034, entitled, "Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor," was presented earlier today in a poster session at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Orlando, Florida. Later this afternoon, the data will also be presented by Dr. Brian Rini, Associate Professor of Medicine at the Cleveland Clinic Taussig Cancer Institute, in a poster discussion during the Genitourinary Cancer session.

The study enrolled a total of 50 patients, of which 46 patients were evaluable for response. Evaluable patients were defined as those who had greater than 7 days of treatment. The primary endpoint of this study was clinical benefit, defined as response rate (RECIST), and progression-free survival (PFS) in RCC patients who failed a prior VEGF receptor inhibitor (sunitinib or sorafenib). Safety of perifosine in this patient population was evaluated as a secondary endpoint. Best response to single agent perifosine was as follows:

      Group     N       PR      SD > 12 wks    CBR*       Median PFS
                       N (%)       N (%)       N (%)       (SD or >)
     All Pts    46    5 (11%)    16 (35%)    21 (46%)      33 weeks
                                                      [95% CI (24, 
'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
2. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
5. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
6. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
7. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
8. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
11. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... --  Sigma-Aldrich Corporation (NASDAQ: SIAL ) a leading ... $50,000 product donation to the Reproducibility Project: Cancer ... from recent high-impact papers in the field of cancer ... research marketplace Science Exchange , the non-profit ... eLife. The goal of the project is ...
(Date:5/6/2015)... 2015 First programme ... and rilpivirine   ViiV Healthcare ... clinical trial programme to evaluate the safety and ... ) as maintenance therapy for adult patients with ... studies evaluating 48 week viral suppression with a ...
(Date:5/5/2015)... BARCELONA, Spain , May 6, 2015 ... and aspires to lead the European market in the ... Through this alliance ECUPHAR acquires all the assets ... the new organization in the coming weeks. Being both ... not been disclosed.      (Photo: http://photos.prnewswire.com/prnh/20150506/743274 ...
Breaking Medicine Technology:Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 2Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 2ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 4ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 5ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 6ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 7ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 8ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 9ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 10ECUPHAR Enters the Spanish and Southern European Markets Through ESTEVE 2
... of its ongoing,efforts to develop research tools that ... disease, The Michael J. Fox,Foundation announced the launch ... the Foundation seeks to drive the creation,and testing ... with a personal,computer and an Internet connection to ...
... March 19 FluoroPharma Inc., a company,developing breakthrough ... (PET) market, announced commencement of Phase,I clinical trials ... the proposed studies. The Phase I trial is ... safety, distribution and dosimetry,of BFPET as a PET ...
Cached Medicine Technology:New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinson's Clinical Trials 2FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2
(Date:5/6/2015)... 2015 Mesa, Arizona (PRWEB) May ... Ag Ventures, Inc. (MAV), an investor backed Colorado ... Arizona based Phoenician Engineering subsidiary three times since ... recently achieved profitability from operations, within one year ... at the end of 2014 to over 500 ...
(Date:5/6/2015)... Established by the Arthritis Foundation, the month of ... Americans who suffer from arthritis. Many who battle this ... symptoms. Medicationdiscountcard.com is proud to offer a prescription ... costs of these necessary prescriptions. , Non-Steroidal Anti-Inflammatory Drugs ... and inflammation in the joints associated with arthritis. Certain ...
(Date:5/6/2015)... Most people in the United States will need at ... age 65. But less than half of people in their ... about it, reports the May 2015 Harvard Health Letter ... is losing control over the care they'll receive. "Many people ... a professor of health care policy at Harvard Medical School. ...
(Date:5/6/2015)... Novodiax announced today that they will ... with Ed Begley Jr., airing via Discovery Channel ... , This segment will explore Novodiax, a company ... will learn about Novodiax’s polymer detection system-based Direct ... scenes to investigate how, based on this technology, ...
(Date:5/6/2015)... A recent National Eye Institute (NEI) ... age, is fully endorsed by fresh water advocate Sharon ... Water® radio show. Kleyne notes, however, that the report ... each day. As Founder and Chairman of Bio-Logic Aqua ... Kleyne has extensive knowledge of vision care, dry eye, ...
Breaking Medicine News(10 mins):Health News:Cannibus Industry Start-Up Reaches Profitability While Expanding Its Proprietary Ancillary Medical Marijuana Product IP Portfolio 2Health News:Medicationdiscountcard.com Provides Access to Drug Coupons for Arthritis Awareness Month 2Health News:Medicationdiscountcard.com Provides Access to Drug Coupons for Arthritis Awareness Month 3Health News:Start Planning Now for Long-Term Care, from the May 2015 Harvard Health Letter 2Health News:Novodiax to Be Featured in Upcoming Episode of Innovations TV Series 2Health News:National Eye Institute’s Eye Care as You Age report endorsed by fresh water advocate Sharon Kleyne – with one addition 2Health News:National Eye Institute’s Eye Care as You Age report endorsed by fresh water advocate Sharon Kleyne – with one addition 3
... economy has been "seizing" uncontrollably. Now a Tel Aviv ... economic downturn with the uncontrolled spasms of an epileptic ... the origins of the disaster. In a recent ... Ben-Jacob of Tel Aviv University,s School of Physics and ...
... released online today, a majority of Americans, including most African ... just as other cigarette flavorings have now been banned by ... African American smokers and 24 percent of white smokers smoke ... by the Center for Child and Adolescent Health Policy at ...
... , THURSDAY, May 12 (HealthDay News) -- Italian researchers ... may actually suffer from a psychological condition known as ... is deficient in the enzyme lactase, which breaks down ... bloating, gas, gut pain and nausea when they eat ...
... Researchers at the Stanford University School of Medicine ... naturally occurring "tumor-suppressor" protein works. The separation of these ... could enhance efforts to develop treatment approaches that ... The protein, p53, is mutated or missing in ...
... May 12 (HealthDay News) -- Mind-body therapies such as yoga, ... in mainstream medicine, according to a new study. ... and that number is rising, the researchers noted. They found ... therapy was referred to the treatment by a medical provider. ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, May 11 ... adults with attention-deficit hyperactivity disorder (ADHD), or the parents of ... finding one that carries the prescription they need to manage ... vary, but much of the focus has been on Adderall ...
Cached Medicine News:Health News:Diagnosing 'seizures' in the US economy 2Health News:African Americans and the general public support banning menthol in cigarettes 2Health News:Lactose Intolerance May Sometimes Be in the Head, Not the Gut 2Health News:Stanford discoveries about tumor-suppressing protein could help to reduce treatment side effects 2Health News:Stanford discoveries about tumor-suppressing protein could help to reduce treatment side effects 3Health News:Doctors Prescribing Meditation, Yoga More Often 2Health News:ADHD Drug Shortage Has Patients, Parents Scrambling 2Health News:ADHD Drug Shortage Has Patients, Parents Scrambling 3
All-natural porcine collagen can be used in open or laparoscopic placement....
... SBI RingFix is a modular external fixation ... large variety of clinical needs. Originally marketed ... has a successful 20 year history of ... Developed around the principles of the Ilizarov ...
... The six models of Thermo Scientific ... mL to 60 mL with very high ... careful design of all components. The Finnpipette ... the extensive Thermo Scientific Finnpipette manual liquid ...
... collection benefits from innovative research in materials ... such as the aerospace and automotive industry, ... and the footwear and textile industry. , ... in the Carrera sunglasses collection to create ...
Medicine Products: